ZimVie Inc. has been fully acquired by ARCHIMED, an investment firm focused on healthcare industries. The transaction was completed at $19.00 per share, resulting in ZimVie being delisted from NASDAQ.

ZimVie Inc. has been fully acquired by ARCHIMED for $19.00 per share, delisting the company from NASDAQ. The transaction represents a strategic move in the dental implant market.

ZIMV earnings call for the period ending March 31, 2024.

MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

These companies are typically uncorrelated to indexes, giving investors a chance to outperform.